Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. RESULTS: After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. CONCLUSIONS: Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combinations of VEGF-targeted agents with anti-PD-1 have demonstrated clinical benefi ts in endometrial carcinoma (pembrolizumab plus lenvatinib; refs.69, 70 ), RCC (pembrolizumab plus axitinib; nivolumab plus cabozantinib; avelumab plus axitinib), and hepatocellular carcinoma (atezolizumab plus bevacizumab; refs.[71][72][73][74][75].”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [71]
In the citing paper
“One study suggested that ICI-colitis correlated with particular strains of microbial flora colonization,19”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Self-citationMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133 · cited 1×
“IMDC risk score is determined by the total number of the following six risk factors that are present: Karnofsky performance-status score of less than 80 (on a scale from 0 to 100, with lower scores indicating greater disability(12)), a time from initial diagnosis to randomization of less than 1 year, a hemoglobin leve…”
MethodSelf-citationKarnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517 · cited 1×
“Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.(12) The programmed death ligand 1 (PD-L1) combined positive score was calculated as the number of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells, multip…”
MethodSystemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Self-citationEscudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Self-citationSternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Self-citation
Research works printed but not linked: 1
- Noone AM, Howlader N, Krapcho M, et al., eds. SEER cancer statistics review (CSR), 1975-2015. Bethesda, MD: National Cancer Institute, 2018 (https://seer .cancer .gov/ csr/ 1975_2015/ ).
Cited by
Items 601–700 of 1,002
Mori, J., Adachi, K., Sakoda, Y., Sasaki, T., Goto, S., Matsumoto, H., Nagashima, Y., Matsuyama, H., & Tamada, K. (2021) · Cancer Science · doi:10.1111/cas.14835 · Cited by 37
Nephrotoxicity of Anti-Angiogenic Therapies
Wynsberghe, M. V., Flejeo, J., Sakhi, H., Ollero, M., Sahali, D., Izzedine, H., & Hénique, C. (2021) · Diagnostics · doi:10.3390/diagnostics11040640 · Cited by 42
Murakami, T., Tanaka, N., Takamatsu, K., Hakozaki, K., Fukumoto, K., Masuda, T., Mikami, S., Shinojima, T., Kakimi, K., Tsunoda, T., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03006-2 · Cited by 43
Msaouel, P., Oromendia, C., Siefker-Radtke, A. O., Tannir, N. M., Subudhi, S. K., Gao, J., Wang, Y., Siddiqui, B. A., Shah, A. Y., Aparicio, A. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.22998 · Cited by 40
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 43
Chan, D. L. H., Rodríguez-Freixinós, V., Doherty, M. K., Wasson, K., Iscoe, N. A., Raskin, W., Hallet, J. I., Myrehaug, S. D., Law, C. H. L., Thawer, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.029 · Cited by 39
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
Thouvenin, J., Alhalabi, O., Carlo, M. I., Carril-Ajuria, L., Hirsch, L., Chanzá, N. M., Négrier, S., Campedel, L., Martini, D. J., Borchiellini, D., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac158 · Cited by 37
Self-citationGrünwald, V., Powles, T. B., Kopyltsov, E., Kozlov, V. V., Alonso‐Gordoa, T., Eto, M., Hutson, T. E., Motzer, R. J., Winquist, E., Maroto, P., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.01.010 · Cited by 43
“Although ICI combination therapies have shown initial survival benefits for advanced/metastatic RCC [7– 9,11 ], long-term survival data are”
BackgroundSelf-citationWen, Y., Ye, S., Li, Z., Zhang, X., Liu, C., Wu, Y., Zheng, R., Xu, C., Tian, J., Shu, L., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03624-y · Cited by 39
“Therefore, it is of great significance for patients to seek effective combined treatment strategies with immune checkpoint inhibitors [7–9].”
BackgroundMotzer, R. J., Escudier, B. J., Burotto, M., Powles, T. B., Apolo, A. B., Bourlon, M. T., Shah, A. Y., Porta, C., Suárez, C., Barrios, C. H., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.09.006 · Cited by 50
Self-citationLandscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia
Maggio, I., Manuzzi, L., Lamberti, G., Ricci, A. D., Tober, N., & Campana, D. (2020) · Cancers · doi:10.3390/cancers12040832 · Cited by 36
Bergmann, L., Grünwald, V., Maute, L., Grimm, M., Weikert, S., Schleicher, J., Klotz, T., Greiner, J., Flörcken, A., Hartmann, A., et al. (2020) · Oncology Research and Treatment · doi:10.1159/000508450 · Cited by 36
Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives
Chacon, M. R., Pflüger, Y., Angel, M. O., Waisberg, F., & Enrico, D. H. (2020) · Cancers · doi:10.3390/cancers12092362 · Cited by 36
Marchioni, M., KRIEGMAIR, M. C., Heck, M., Amiel, T., Porpiglia, F., Ceccucci, E., Campi, R., Minervini, A., Mari, A., Bruwaene, S. V., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.12.010 · Cited by 36
Wattenberg, M. M., Herrera, V. M., Giannone, M. A., Gladney, W. L., Carpenter, E. L., & Beatty, G. L. (2021) · JCI Insight · doi:10.1172/jci.insight.145389 · Cited by 38
“74 T cell immunotherapy, such as with monoclonal antibodies (mAb) targeting CTLA75 4 and PD-1/PD-L1 checkpoint proteins, have shown remarkable activity in patients with 76 lung cancer, kidney cancer and melanoma (6-8), but have failed to improve outcomes for 77 patients with PDA (9, 10).”
BackgroundHow low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy
Fundytus, A. M., Booth, C. M., & Tannock, I. F. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.208 · Cited by 36
Rizzo, A., Mollica, V., Dall’Olio, F. G., Ricci, A. D., Maggio, I., Marchetti, A., Rosellini, M., Santoni, M., Ardizzoni, A., & Massari, F. (2021) · Future Oncology · doi:10.2217/fon-2021-0069 · Cited by 36
Control of Tumor Progression by Angiocrine Factors
Alsina‐Sanchís, E., Mülfarth, R. I., & Fischer, A. (2021) · Cancers · doi:10.3390/cancers13112610 · Cited by 39
“non-small cell lung carcinoma demonstrated that antiangiogenic therapy targeting VEGF synergizes with immunotherapy targeting the PD-1/PD-L1 axis [121,122].”
BackgroundDemasure, S., Spriet, I., Debruyne, P. R., Laenen, A., Wynendaele, W., Baldewijns, M. M. L. L., Dumez, H., Clement, P. M., Wildiers, H. P. M. W., Schöffski, P., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1989720 · Cited by 38
Liu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 41
Graham, J., Wells, J. C., Dudani, S., Gan, C. L., Donskov, F. N., Lee, J., Kollmannsberger, C., Meza, L., Beuselinck, B., Hansen, A. R., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.002 · Cited by 36
Zhou, X., Wu, J., Duan, C., & Liu, Y. (2020) · Journal of Immunology Research · doi:10.1155/2020/7890985 · Cited by 39
Peng, X., Huang, X., Lulu, T. B., Jia, W., Zhang, S., Cohen, L., Huang, S., Fan, J., Chen, X., Liu, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01978-0 · Cited by 37
Tannir, N. M., Formiga, M. N., Penkov, K., Kislov, N. V., Vasiliev, A., Skare, N. G., Hong, W., Dai, S., Tang, L., Qureshi, A. H., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02082 · Cited by 41
Self-citationBest practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
Yamauchi, I., & Yabe, D. (2025) · European Thyroid Journal · doi:10.1530/etj-24-0328 · Cited by 45
Elkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 43
Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC)
Rysz, J., Ławiński, J., Franczyk, B., & Gluba-Brzózka, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125577 · Cited by 37
“At the initial analysis, after a median follow-up of 12.8 months, the combination therapy demonstrated a significant improvement in outcomes compared to sunitinib [11].”
InfluentialChen, J., Hu, G., Chen, Z., Wan, X., Tan, C., Zeng, X., & Cheng, Z. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00820-6 · Cited by 35
“Grade 3, 4 or 5 AEs that had significantly different rates between treatments in the KEYNOTE-426 trial were included in the model [8], which were diarrhea, fatigue, alanine aminotransferase increased (ALT), aspartate aminotransferase increased (AST), anemia, thrombocytopenia and neutropenia.”
BackgroundMethodInfluentialMechanism‐based treatment of cancer with immune checkpoint inhibitor therapies
Abdou, Y. G., Pandey, M. R., Sarma, M., Shah, S., Baron, J. I., & Ernstoff, M. S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14316 · Cited by 36
“has received approval for use in RCC and endometrial cancer.(88,93,105,106) Similarly, other trials are looking at combinations of anti-PD-1/PD-L1 with other TME-related immunosuppressive mole-”
MethodIribe, Y., Furuya, M., Shibata, Y., Yasui, M., Funahashi, M., Ota, J., Iwashita, H., Nagashima, Y., Hasumi, H., Hayashi, N., et al. (2020) · Familial Cancer · doi:10.1007/s10689-020-00195-0 · Cited by 38
Su, Y.-J., Fu, J., Du, J., & Wu, B. Y. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920950199 · Cited by 35
Tumour vasculature: Friend or foe of oncolytic viruses?
Santry, L. A., van Vloten, J. P., Knapp, J. P., Matuszewska, K., McAusland, T. M., Minott, J. A., Mould, R. C., Stegelmeier, A. A., Major, P. P., Wootton, S. K., et al. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.07.007 · Cited by 37
Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
Roberto, M., Botticelli, A., Panebianco, M., Aschelter, A. M., Gelibter, A. J., Ciccarese, C., Minelli, M., Nuti, M., Santini, D., Laghi, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657639 · Cited by 39
“001) in favor of the combined treatment arm, disregarding the status of PD-L1 and the prognostic risk category (47).”
BackgroundResultStereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
Schoenhals, J. E., Mohamad, O., Christie, A. L., Zhang, Y., Li, D., Singla, N., Bowman, I. A., Arafat, W., Hammers, H. J., Courtney, K. D., et al. (2021) · Advances in Radiation Oncology · doi:10.1016/j.adro.2021.100692 · Cited by 38
Zhang, Z., Yang, C., Li, L., Zhu, Y., Su, K., Zhai, L., Wang, Z., & Huang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.699478 · Cited by 46
“The clinical trials, like KEYNOTE-426 and IMbrave 150, found that full or high dose anti-VEGFR2 therapy plus PD-1 inhibitor significantly longer survival in some tumor types, which implied that high dose antiVEGFR2 therapy closely related to the inhibitory immune microenvironment (48, 49).”
MethodFacts and Hopes for Immunotherapy in Renal Cell Carcinoma
Yao, C., Zhang, T., Wu, T., & Brugarolas, J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2372 · Cited by 37
Role of metastasectomy in the management of renal cell carcinoma
Mikhail, M., Chua, K. J., Khizir, L., Tabakin, A. L., & Singer, E. A. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.943604 · Cited by 38
Understanding the Tumor Immune Microenvironment in Renal Cell Carcinoma
Shapiro, D. D., Dolan, B. K., Laklouk, I. A., Rassi, S., Ložar, T., Emamekhoo, H., Wentland, A. L., Lubner, M. G., & Abel, E. J. (2023) · Cancers · doi:10.3390/cancers15092500 · Cited by 41
Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Younis, A., & Gribben, J. G. (2024) · Immuno · doi:10.3390/immuno4030013 · Cited by 42
Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Cimadamore, A., Liang Cheng, C., Antonio Lopez-beltran, B., Montironi, R., Pisconti, S., Battelli, N., et al. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00773-w · Cited by 34
Lü, J., Yang, J., Liang, Y., Meng, H., Zhao, J., & Zhang, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01453 · Cited by 36
Chanzá, N. M., Xie, W., Issa, M., Dzimitrowicz, H. E., Tripathi, A., Beuselinck, B., Lam, E. T., Zakharia, Y., McKay, R. R., Shah, S. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000538 · Cited by 35
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
de Almeida, D. V. P., Fong, L. H., Rettig, M. B., & Autio, K. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_278853 · Cited by 40
Barth, D. A., Drulă, R., Ott, L. F., Fabris, L., Slabý, O., Călin, G. A., & Pichler, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00828 · Cited by 34
The Immunotherapy Landscape in Renal Cell Carcinoma
Brown, L. C., Desai, K. B., Zhang, T., & Ornstein, M. C. (2020) · BioDrugs · doi:10.1007/s40259-020-00449-4 · Cited by 37
Brown, J. T., Liu, Y., Shabto, J. M., Martini, D. J., Ravindranathan, D., Hitron, E., Russler, G. A., Caulfield, S. E., Yantorni, L. B., Joshi, S. S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002851 · Cited by 34
Zhao, L.-P., Hu, J.-H., Hu, D., Wang, H., Huang, C.-G., Luo, R., Zhou, Z.-H., Huang, X., Xie, T., & Lou, J.-S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112949 · Cited by 37
Daly, R. J., Scott, A. M., Klein, O., & Ernst, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01656-z · Cited by 40
“6), culminating in FDA-approval for pembrolizumab or Avelumab and Axitinib for renal cell carcinoma [92, 93], pembrolizumab and Lenvatinib in endometrial carcinoma [94], Atezolizumab, Bevacizumab and chemotherapy in non-squamous non-small cell lung cancer [95] and Atezolizumab and Bevacizumab in unresectable hepatocel…”
BackgroundChoueiri, T. K., Powles, T. B., Voss, M. H., Plimack, E. R., Gurney, H., Song, Y., Perini, R. F., Rodriguez-Lopez, K., & Rini, B. I. (2023) · Future Oncology · doi:10.2217/fon-2023-0283 · Cited by 42
Self-citationBelzutifan for the treatment of renal cell carcinoma
Wu, X., Lazris, D., Wong, R. L., & Tykodi, S. S. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251317846 · Cited by 37
Bex, A., Thienen, J. V., Schrier, M., Graafland, N. M., Kuusk, T., Hendricksen, K., Lagerveld, B. W., Zondervan, P. J., van Moorselaar, R. J. A., Blank, C. U., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0111 · Cited by 36
Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma
Parikh, M., & Bajwa, P. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.12.009 · Cited by 39
“The Phase III KEYNOTE-426 trial then randomized treatment-naïve mRCC patients to receive either pembrolizumab plus axitinib or sunitinib [28].”
BackgroundMethodImmunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment
Masaoutis, C., Kokkali, S., & Theocharis, S. E. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1898587 · Cited by 42
“axitinib and pembrolizumab in renal cell carcinoma are treatment paradigms [110,111].”
BackgroundPletcher, J. P., Bhattacharjee, S., Doan, J. P., Wynn, R. R., Sindhwani, P., Nadiminty, N., & Petros, F. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681441 · Cited by 33
“Hence, immune checkpoint inhibitors (CPIs), such as nivolumab, pembrolizumab, and ipilimumab, now constitute the mainstay of mRCC treatment (26, 27).”
BackgroundYuan, M., Zhu, Z., Mao, W., Wang, H., Qian, H., Wu, J., Guo, X., & Xu, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683502 · Cited by 33
“Combination therapy with pembrolizumab and axitinib was approved by the FDA for treatment-naïve patients with metastatic renal cell carcinoma (RCC) (38).”
MethodCombination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?
Rossi, E., Bersanelli, M., Gelibter, A. J., Borsellino, N., Caserta, C., Doni, L., Maruzzo, M., Mosca, A., Pisano, C., Verzoni, E., et al. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01140-9 · Cited by 37
Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
Michaelis, J., Grabbert, M. T., Sigle, A., Yılmaz, M., Schlager, D., Gratzke, C., Miernik, A. J., & Schoeb, D. S. (2022) · Cancers · doi:10.3390/cancers14153777 · Cited by 35
“0001) for combination therapy [9] as well.”
Büttner, F., Winter, S., Stühler, V., Rausch, S., Hennenlotter, J., Fuessel, S., Zastrow, S., Meinhardt, M., Toma, M. I., Jerónimo, C., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01105-y · Cited by 35
Self-citationJin, S., Zhao, R., Zhou, C., Zhong, Q., Shi, J., Su, C., Li, Q., Su, X., Chi, H., Lu, X., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34372 · Cited by 39
“These results suggest that the outcomes of such combination are more favorable than those of monotherapies reported in previous studies, and it is likely to be attributed to the synergistic effects of ICIs and antiangiogenic agents.(22) Patients with advanced or recurrent BTC often experience a rapid decline in perfor…”
BackgroundResultDanlos, F., Texier, M., Job, B., Mouraud, S., Cassard, L., Baldini, C., Varga, A., Yurchenko, A. A., Rabeau, A., Champiat, S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0886 · Cited by 33
Santoni, M., Massari, F., Myint, Z. W., Iacovelli, R., Pichler, M., Basso, U., Kopecký, J., Kucharz, J., Buti, S., Salfi, A., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.03.006 · Cited by 35
Evolution of the HIF targeted therapy in clear cell renal cell carcinoma
Golijanin, B., Malshy, K., Khaleel, S. S., Lagos, G., Amin, A., Cheng, L., Golijanin, D., & Mega, A. E. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102645 · Cited by 36
Dougan, M. L. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-020-0752-z · Cited by 36
Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review
Zhang, H., Houadj, L., Wu, K. Y., & Tran, S. D. (2024) · Diagnostics · doi:10.3390/diagnostics14030336 · Cited by 38
Adashek, J. J., Genovese, G., Tannir, N. M., & Msaouel, P. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100166 · Cited by 34
Quintela-Fandiño, M., Holgado, E., Manso, L., Morales, S. M., Bermejo, B., Colomer, R., Apala, J. V., Blanco, R., Muñoz, M., Caleiras, E. J., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01362-y · Cited by 35
Arias-Pinilla, G. A., & Modjtahedi, H. (2021) · Cancers · doi:10.3390/cancers13081781 · Cited by 35
Ikeda, T., Ishihara, H., Nemoto, Y., Tachibana, H., Fukuda, H., Yoshida, K., Takagi, T., Iizuka, J., Hashimoto, Y., Ishida, H., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.05.012 · Cited by 34
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
Anderson, T. S., McCormick, A. L., Piersall, S. L., Okpalanwaka, I. F., & Lowe, D. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.009 · Cited by 37
Vauchier, C., Auclin, É., Barthélémy, P., Carril-Ajuria, L., Ryckewaert, T., Borchiellini, D., Ajgal, Z. C., Bennamoun, M., Campedel, L., Thiery-Vuillemin, A., et al. (2022) · Journal of Oncology · doi:10.1155/2022/3449660 · Cited by 32
“While PD-L1 expression and the tumor mutational burden were not associated with better outcomes, compared to melanoma and NSCLC, biomarkers from TME are promising but still need further investigation and validation in RCC [4, 5, 24, 32].”
BackgroundSelf-citationLiu, K., Zhao, S., Li, J., Zheng, Y., Wu, H., Kong, J., & Shen, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.969217 · Cited by 36
Jamal, R., Messaoudene, M., de Figuieredo, M., & Routy, B. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101754 · Cited by 31
Ocadlikova, D., Lecciso, M., Broto, J. M., Scotlandi, K., Cavo, M., Curti, A., & Palmerini, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.577766 · Cited by 31
Roskoski, R. J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107181 · Cited by 31
Watanabe, K., Sugiyama, T., Otsuka, A., & Miyake, H. (2019) · International Cancer Conference Journal · doi:10.1007/s13691-019-00389-z · Cited by 31
Zhou, X., Hou, W., Gao, L., Shui, L., Cheng, Y., & Zhu, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01321 · Cited by 32
“sunitinib monotherapy in treatment-naïve patients with mRCC (69, 70).”
Gamat, M., Jeon, D., Johnson, L. E., Moseman, J. E., Muralidhar, A., Potluri, H. K., Rastogi, I., Wargowski, E., Zahm, C. D., & McNeel, D. G. (2020) · Cancers · doi:10.3390/cancers12102831 · Cited by 32
“Immune checkpoint blockade monotherapy has shown remarkable clinical efficacy in a variety of cancer types including melanoma [100], renal cell carcinoma [101], and nonsmall cell lung cancer [102].”
BackgroundThe human microbiome and genitourinary malignancies
Nicolaro, M., Portal, D. E., Shinder, B. M., Patel, H. V., & Singer, E. A. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2976 · Cited by 31
“Immune checkpoint blockade via the PD-1/PD-L1 and CTLA-4 pathways has demonstrated durable responses, with various FDA approved agents now available for both urothelial and kidney cancers (34,38,64-68).”
BackgroundPatel, V. M., Elias, R. M., Formella, J., Schwartzman, W. S., Christie, A. L., Cai, Q., Malladi, V. S., Kapur, P., Vazquez, M., McKay, R. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001198 · Cited by 33
Thyroid gland metastasis from renal cell carcinoma: a case series and literature review
Tjahjono, R., Phung, D., Gurney, H., Gupta, R., Riffat, F., & Palme, C. E. (2020) · ANZ Journal of Surgery · doi:10.1111/ans.16482 · Cited by 31
“Metastatic disease carries a poor prognosis, with a median overall survival of 2 years and a 5-year survival rate of 10%,(2,4) although survival has substantially improved recently with the introduction of effective systemic therapies.(17,18) Metastatic disease to the thyroid gland is uncommon, only comprising of 2% o…”
BackgroundPrognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma
Kotecha, R. R., Flippot, R., Nortman, T., Guida, A., Patil, S., Escudier, B. J., Motzer, R. J., Albiges, L. K., & Voss, M. H. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7634 · Cited by 34
Lee, C., DiNatale, R. G., Chowell, D., Krishna, C., Makarov, V., Valero, C., Vuong, L. H., Lee, M., Weiss, K. L., Hoen, D., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0053 · Cited by 36
Tzeng, A., Tzeng, T. H., & Ornstein, M. C. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003473 · Cited by 35
“44 Importantly, a subsequent analysis of patients in this trial who completed 2 years of therapy demonstrated that a high proportion had ongoing clinical benefit.”
Walsh, R. J., & Tan, D. S. P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194523 · Cited by 36
“Such combination strategies have shown a survival benefit in NSCLC [66], hepatocellular carcinoma [67] and renal cell carcinoma [68].”
BackgroundThe roaring 2020s: a new decade of systemic therapy for renal cell carcinoma
Srivastava, A., Doppalapudi, S. K., Patel, H. V., Srinivasan, R., & Singer, E. A. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000831 · Cited by 31
“In a subgroup analysis, however, OS benefit was not seen in patients with favorable risk disease [21].”
BackgroundLiu, Y., Zhang, Z., Wang, S., Fu, S., Cheng, X., Chen, R., & Sun, T. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108900 · Cited by 35
Rebuzzi, S. E., Perrone, F., Bersanelli, M., Bregni, G., Milella, M., & Buti, S. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1680286 · Cited by 32
“The magnitude of PFS and OS benefit was higher in the intermediate and poor-risk subgroup compared to the favorable one in three of these studies (for PFS [30], OS [23] and both [29]).”
BackgroundMethodResultInfluentialAtkins, M. B., Rini, B. I., Motzer, R. J., Powles, T. B., McDermott, D. F., Suárez, C., Bracarda, S., Stadler, W. M., Donskov, F. N., Gurney, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2838 · Cited by 32
“0001) versus sunitinib as first-line treatment for mRCC across risk groups (6, 10).”
BackgroundSelf-citationDing, X., Hua, Y., Zou, X., Chen, X., Zhang, X., Xu, B., Ouyang, Y., Tu, Z., Li, H., Duan, C., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102043 · Cited by 31
Self-citationHuang, J., Wang, Y., Xu, F., Wang, Z., Wu, G., Kong, W., Ng, C., Tricard, T., Wu, X., Zhai, W., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008475 · Cited by 33
Zarif, T. E., Semaan, K., Xie, W., Eid, M., Zarbá, M., Issa, W., Zhang, T., Nguyen, C. B., Alva, A. S., Fahey, C. C., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.07.016 · Cited by 30
Self-citationImmunotherapy in colorectal cancer
Agarwal, P., Le, D. T., & Boland, P. M. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.03.002 · Cited by 35
Wang, J., Li, X., Wu, X., Wang, Z., Zhang, C., Cao, G., Zhang, X., Peng, F., & Yan, T. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.006 · Cited by 32
“The results of KEYNOTE-426 trial was consistent with ours, showing that pembrolizumab plus axitinib resulted in significantly longer OS and PFS than sunitinib [11].”
BackgroundResultInfluentialSantoni, M., Heng, D. Y. C., Sergio Bracarda, A., Procopio, G., Milella, M., Porta, C., Matrana, M. R., Cartenì, G., Crabb, S. J., Giorgi, U. D., et al. (2019) · Cancers · doi:10.3390/cancers12010084 · Cited by 30
“, sunitinib, pazopanib, sorafenib, axitinib and tivozanib [2–9]) have demonstrated activity in metastatic RCC (mRCC), as well as immunecheckpoint inhibitors used alone as nivolumab [10] or combined with other immunotherapy (nivolumab plus ipilimumab [11]) or targeted therapies (axitinib plus pembrolizumab or avelumab)…”
BackgroundIivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
“At present, clinically the most relevant therapeutic uses for anti-PD-(L)1-anti-CTLA-4 antibody combinations are in advanced melanoma [113], RCC [114], and NSCLC [115], anti-PD-(L)1 antibody -chemo in lung cancers [116,117] and triple-negative breast cancer [118], and anti-PD-(L)1 antibody -TKI in RCC [119].”
BackgroundMa, J., Song, Y., Shou, J., Bai, Y., Li, H., Xie, X., Luo, H., Ren, X., Liu, J., Ye, D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00664 · Cited by 32
Tomita, Y., Tatsugami, K., Nakaigawa, N., Osawa, T., Oya, M., Kanayama, H., Kondoh, C. N., Sassa, N., Nishimura, K., Nozawa, M., et al. (2020) · International Journal of Urology · doi:10.1111/iju.14329 · Cited by 32
Self-citationModest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma
Tachibana, H., Kondo, T., Ishihara, H., Fukuda, H., Yoshida, K., Takagi, T., Izuka, J., Kobayashi, H., & Tanabe, K. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa229 · Cited by 32
Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date
Tacconi, E. M., Tuthill, M. H., & Protheroe, A. S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s174149 · Cited by 35
“In KEYNOTE-426 the combination of axitinib and pembrolizumab was superior to sunitinib alone, extending both OS and PFS in patients with metastatic disease.(15) Several trials are ongoing assessing various combinations of TKIs and ICIs in metastatic RCC, including CheckMate 9ER, COSMIC-313 and CLEAR.”
BackgroundCurrent status of PD-1/PD-L1 blockade immunotherapy in breast cancer
Noguchi, E., Shien, T., & Iwata, H. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa230 · Cited by 30
Metadata
- Authors
- Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., Vynnychenko, I., Kryzhanivska, A., Bondarenko, I., Azevedo, S. J., Borchiellini, D., Szczylik, C., Markus, M., McDermott, R. S., Bedke, J., Tartas, S., Chang, Y.-H., Tamada, S., Shou, Q., Perini, R. F., Chen, M., Atkins, M. B., & Powles, T.
- Affiliations
- Fox Chase Cancer Center (US)
- From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) — all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Rini, Brian I.
- Plimack, Elizabeth R.
- Stus, Viktor
- Gafanov, Rustem
- Nosov, Dmitry
- Pouliot, Frédéric
- Alekseev, Boris
- Soulières, Denis
- Melichar, Bohuslav
- Vynnychenko, Ihor
- Kryzhanivska, Anna
- Bondarenko, Igor
- Borchiellini, Delphine
- Szczylik, Cezary
- Bedke, Jens
- Tamada, Satoshi
- Perini, Rodolfo F.
- Atkins, Michael B.
- Powles, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-21
- Volume
- 380
- Issue
- 12
- Pages
- 1116-1127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2913745075
- Cited by
- 3,403
- References
- 23
- Citations by year
- 2026: 269 · 2025: 323 · 2024: 431 · 2023: 440 · 2022: 589 · 2021: 597 · 2020: 532 · 2019: 220
- FWCI
- 357.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Oncourology (Russian Society of Oncourologists) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pembrolizumab, axitinib, sunitinib, immune checkpoint inhibitors, PD-1 inhibitors, PD-L1 expression, overall survival, progression-free survival, objective response rate, first-line therapy, adverse events, immune-related adverse events, tyrosine kinase inhibitors, IMDC risk groups
- MeSH terms
- Sunitinib, Axitinib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Survival Rate, Single-Blind Method, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.